Company: BLNE
Filing Date: 2025-03-27
Form Type: 424B7
Source: 0001641172-25-000822
Chunk: 14

Company: Beeline Holdings, Inc.
Filing Date: 2025-03-27
Form: 424B7
Chunk 14
---
 able to secure working capital from other sources including an at-the-market offering. We recently executed an engagement letter with a broker-dealer which will be or exclusive sales agent under an at-the-market offering. Subject to their due diligence and customary conditions, we expect a definitive At-the Market Offering Agreement in April 2025. We cannot assure you we will receive any proceeds from the at-the-market offering. Further, the two concurrent offerings may result in us using the at-the-market offering since it will entail a 3% commission. If obtaining sufficient funding from C/M were to prove unavailable or prohibitively dilutive, we will need to secure another source of funding in order to satisfy our working capital needs. Even if we sell the maximum amount of $10 million of shares of common stock to C/M under the Purchase Agreement, we may still need additional capital to fully implement our business, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it or expose us to substantial restrictive covenants or limitations, the consequences could be a material adverse effect on our business, operating results, financial condition and prospects.

The sale of our common stock to C/M will cause dilution and the sale of the shares by C/M could cause the price of our common stock to decline.

The number of shares ultimately offered for sale by C/M is dependent upon the number of shares sold to C/M under the Purchase Agreement. The purchase price for the common stock to be sold to C/M pursuant to the Purchase Agreement will fluctuate based on the price of our common stock. Depending upon market liquidity at the time, a sale of shares by C/M at any given time could cause the trading price of our common stock to decline. After it has acquired such shares, C/M may sell all, some or none of such shares, although we expect it will not be a long-term investor with the ELOC shares. Therefore, sales to C/M by us under the Purchase Agreement will result in substantial dilution to the interests of other holders of our common stock. The sale of a substantial number of shares of our common stock, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. However, we have the right to control the timing and amount of any sales of our shares to C/M.

| S-17 |

Our management might apply the net proceeds from sales by us